loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Fosmanogepix

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Fosmanogepix

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Basilea Starts Phase 3 Study Of Fosmanogepix In Candidiasis
    Basilea Starts Phase 3 Study Of Fosmanogepix In Candidiasis

    23 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/24/2951846/0/en/Basilea-initiates-clinical-phase-3-study-with-antifungal-fosmanogepix-in-candidemia-and-invasive-candidiasis.html

    GLOBENEWSWIRE
    23 Sep 2024
    Share Share
    Basilea Partners With BARDA For Novel Antimicrobials
    Basilea Partners With BARDA For Novel Antimicrobials

    19 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/19/2948711/0/en/Basilea-enters-into-agreement-with-BARDA-to-develop-novel-antifungals-and-antibacterials-and-receives-initial-funding.html

    GLOBENEWSWIRE
    19 Sep 2024
    Share Share